ELIQUIS® (apixaban) Data Analyses To Be Presented At European Society Of Cardiology Congress 2012

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that multiple data presentations on ELIQUIS ^® (apixaban) will be presented at the European Society of Cardiology Congress 2012, August 25-29, 2012, in Munich, Germany. New data will be presented, including a prespecified subanalysis from the ARISTOTLE trial that evaluated the efficacy and safety of ELIQUIS ^® compared to warfarin in relation to renal function in patients with nonvalvular atrial fibrillation. Results of this analysis will be presented during a Clinical Trial Update session on August 29, 2012 and accompanying webcast.

Details on this data analysis and other studies at the congress are as follows:

Session Details

Presentation Title

Lead Author

Sunday August 26, 2012 8:30 – 12:30 CEST Room Posters – Village 10(P553)

Increased levels of D-dimer identify patientswith atrial fibrillation at high risk for bleedingan ARISTOTLE substudy

Agneta Siegbahn, MD, PhDUppsala UniversityUppsala, SE

Sunday August 26, 2012 8:30 – 12:30 CEST Room Posters – Village 10(P551)

NT-proBNP for risk stratification in atrialfibrillation during treatment with apixaban orwarfarin

Lars C. Wallentin, MD, PhDUppsala UniversityUppsala, SE

Sunday August 26, 2012 8:30 – 12:30 CEST Room Posters – Village 10(P554)

Effect of apixaban on all-cause mortalityin atrial fibrillation: an imputed placebo analysis

John J.V. McMurray, MDUniversity of GlasgowGlasgow, GB

Sunday August 26, 2012 8:30 – 12:30 CEST Room Posters – Village 10(P558)

High sensitivity troponin-T for riskstratification in atrial fibrillation duringtreatment with apixaban or warfarin

Lars C. Wallentin, MD, PhDUppsala UniversityUppsala, SE

Sunday August 26, 2012 8:30 – 12:30 CEST Room Posters – Village 10(P559)

How well are atrial fibrillation (AF) patients inthe real world represented in the ContemporaryNovel Oral Anticoagulant (NOAC) AF trials?

Teresa SimonBristol-Myers Squibb CompanyPrinceton, NJ, U.S.

Sunday August 26, 2012 8:30 – 12:30 CEST Room Posters – Village 10(P563)

Cost-effectiveness of apixaban against othernovel oral anticoagulants (NOACs) for strokeprevention in atrial fibrillation patients

Gregory YH Lip, MDUniversity of BirminghamBirmingham, GB

Sunday August 26, 2012 14:00 – 18:00 CEST Room Posters – Village 10(P1555)

Heterogeneity in published evidence for strokeprevention in patients with atrial fibrillation: asystematic review

David E. Jakouloff, MD, PhDBristol-Myers Squibb CompanyRueil-Malmaison, FR

Sunday August 26, 2012 14:00 – 18:00 CEST Room Posters – Village 10(P1793)

Cost of venous thromboembolism inhospitalized medically ill patients

Trudy PendergraftPolicy Analysis, Inc.Brookline, MA, U.S.

Sunday August 26, 2012 14:00 – 18:00 CEST Room Posters – Village 10(P1953)

Apixaban after acute coronary syndrome inpatients with heart failure: insights from theAPPRAISE-2 trial

Jan H. Cornel, MD, PhDMedical Center AlkmaarAlkmaar, NL

Monday August 27, 2012 17:45 – 18:00 CEST Room Reykjavik – Village 5(Oral Session: 3156)

Risk of stroke, systemic embolism or deathaccording to heart failure and leftventricular function status in patients withatrial fibrillation: results of the ARISTOTLE trial

John J.V. McMurray, MDUniversity of GlasgowGlasgow, GB

Tuesday August 28, 2012 11:30 – 11:45 CEST Room Tel Aviv – Village 7(Oral Session: 4045)

Events after discontinuation of randomizedtreatment at the end of the ARISTOTLE trial

Christopher B. Granger, MDDuke UniversityDurham, NC, U.S.

Tuesday August 28, 2012 12:15 – 12:30 CEST Room Tel Aviv – Village 7(Oral Session: 4048)

Apixaban and warfarin are associated with alow risk of stroke following cardioversionfor atrial fibrillation: results from the ARISTOTLEtrial

Greg C. Flaker, MDUniversity of Missouri School of MedicineColumbia, MO, U.S.

Tuesday August 28, 2012 14:00 – 18:00 CEST Room Posters – Village 10(P5015)

Discharge status of atrial fibrillation patientshospitalized for ischemic or hemorrhagic strokein the United States

Teresa SimonBristol-Myers Squibb CompanyPrinceton, NJ, U.S.

Wednesday August 29, 2012 9:30 – 9:45 CEST Room Brussels – Village 7(Oral Session: 5294)

Cost-effectiveness of apixaban against currentstandard of care (SoC) for stroke prevention inatrial fibrillation patients

Paul Dorian, MD, MSc, FRCPUniversity of TorontoToronto, CA

Wednesday August 29, 2012 8:45 – 9:00 CEST Room Tallinn – Village 7(Oral Session: 5297)

Increased levels of D-dimer in atrial fibrillationidentify patients with higher risk ofthromboembolic events and death

Christina Christersson, MD, PhDUppsala UniversityUppsala, SE

Wednesday August 29, 2012 8:46 – 8:57 CEST Clinical Trial and Registry Update, Webcast Room Munich – Central Village (Oral Session: 5172)

ARISTOTLE: Efficacy of apixaban ascompared with warfarin in relation to renalfunction in patients with atrial fibrillation -Insights from the ARISTOTLE Trial

Stefan H. Hohnloser, MDGoethe UniversityFrankfurt, DE

About Atrial Fibrillation

Atrial fibrillation is the most common cardiac arrhythmia (irregular heart beat). It estimated that more than 5.8 million Americans and 6 million individuals in Europe have atrial fibrillation. The lifetime risk of developing atrial fibrillation is estimated to be approximately 25 percent for individuals 40 years of age or older. One of the most serious medical concerns for individuals with atrial fibrillation is the increased risk of stroke, which is five times higher in people with atrial fibrillation than those without atrial fibrillation. In fact, 15 percent of all strokes are attributable to atrial fibrillation in the U.S. Additionally, strokes due to atrial fibrillation are more burdensome than strokes due to other causes. Atrial fibrillation-related strokes are more severe than other strokes, with an associated 30-day mortality of 24 percent and a 50 percent likelihood of death within one year in patients who are not treated with an antithrombotic.

1 2 3 Next › Last »